• 1
    LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-2476.
  • 2
    Merck & Company, Inc. Sinemet (carbidopa-levodopa) [prescribing information]. Whitehouse Station, NJ: Merck & Company, Inc.; 2011.
  • 3
    LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 2009;24:1319-1324.
  • 4
    Pahwa R, Factor SA, Lyons KE, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995.
  • 5
    Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005;32:459-484.
  • 6
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
  • 7
    Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45:109-136.
  • 8
    Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord 2008;23:S599-S612.
  • 9
    Aton Pharma, Inc. Lodosyn (carbidopa) tablet [package insert]. Bridgewater, NJ: Aton Pharma, Inc.; 2011.
  • 10
    LeWitt PA, Ellenbogen A, Chen D, et al. Actively-transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharm 2012;35:103-110.
  • 11
    Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
  • 12
    Fahn S, Elton RL; members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
  • 13
    Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241-248.
  • 14
    Guy W. ECDEU Assessment Manual for Psychopharmacology. Publication no. (ADM) 76–338. Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare; 1976. Available at: Accessed February 1, 2013.
  • 15
    Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with “on-off” fluctuations. Neurology 1993;43:1698-1703.
  • 16
    Cook RD. Influential observations in linear regression. J Am Stat Assoc 1979;74:169-174.
  • 17
    Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
  • 18
    Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
  • 19
    Rascol O. Rasagiline in the pharmacotherapy of Parkinson's disease—a review. Expert Opin Pharmacother 2005;6:2061-2075.